keyword
MENU ▼
Read by QxMD icon Read
search

Intravesical BCG

keyword
https://www.readbyqxmd.com/read/28627636/formulation-and-characterization-of-egcg-for-the-treatment-of-superficial-bladder-cancer
#1
Katarzyna Dettlaff, Maciej Stawny, Magdalena Ogrodowczyk, Anna Jelińska, Waldemar Bednarski, Dorota Wątróbska-Świetlikowska, Rick W Keck, Omar A Khan, Ibrahim H Mostafa, Jerzy Jankun
In the United States, the annual incidence of bladder cancer is approximately 70,000 new cases, with a mortality rate of approximately 15,000/year. The most common subtype (70%) of bladder cancer is superficial, namely hte non-muscle invasive disease form limited to the urothelium. The rate of progression and recurrence is up to 40 and 70%, respectively. Urothelial cell carcinoma of the bladder is typically treated with transurethral resection. The cancerous cells can float onto the adjacent epithelium, increasing the risk of recurrence...
June 14, 2017: International Journal of Molecular Medicine
https://www.readbyqxmd.com/read/28626185/miliary-tuberculosis-that-developed-after-intravesical-bacillus-calmette-guerin-therapy
#2
Kyohei Kaburaki, Keishi Sugino, Muneyuki Sekiya, Yujiro Takai, Kazutoshi Shibuya, Sakae Homma
As a treatment for superficial transitional cell carcinoma, Bacillus Calmette-Guerin (BCG) intravesical instillation can rarely cause unpredictable systemic side effects. We describe a patient admitted due to continuous pyrexia and general fatigue. He was previously treated with intravesical BCG. Laboratory data indicated a hepatic disorder, and chest computed tomography revealed extensive bilateral miliary nodules. Transbronchial lung biopsy specimens showed several small noncaseating granulomas. The diagnosis was unsolved on the basis of acid fast staining, polymerase chain reaction and microbiological cultures, so we considered the possibility of BCG side effect-induced granuloma...
2017: Internal Medicine
https://www.readbyqxmd.com/read/28609792/-systematic-review-on-conservative-treatment-options-in-non-muscle-invasive-bladder-cancer-patients-refractory-to-bacillus-calmette-gu%C3%A3-rin-instillation-therapy
#3
Thomas Martini, Felix Wezel, Niklas Löbig, Michael J Mitterberger, Daniela Colleselli
Background Adjuvant Bacillus Calmette-Guérin (BCG) intravesical instillation is the recommended standard treatment in patients with high-risk non-muscle-invasive bladder cancer (NMIBC). However, a significant proportion of patients fail treatment, and radical cystectomy (RC) is the subsequent gold standard. On the other hand, there is an unmet need for conservative alternatives for patients who are unfit or unwilling to undergo surgery. This study aimed to identify conservative treatment options in NMIBC patients after BCG failure...
June 13, 2017: Aktuelle Urologie
https://www.readbyqxmd.com/read/28607879/intravesical-alt-803-for-bcg-unresponsive-bladder-cancer-a-case-report
#4
Jeffrey Huang, John Schisler, Hing C Wong, Charles J Rosser, Joseph Sterbis
The administration of intravesical chemotherapy or BCG often can prolong the progression-free interval after initial transurethral resection in select bladder cancer (BCa) patients. However, 60% of these patients will recur and up to 30% of patients with recurrent BCa will progress and succumb to their disease over a 15 year period, while another 50% will cystectomy in an attempt to control their disease. Thus better therapeutic strategies are needed for patients who have failed intravesical therapy. In this article, we report the treatment of a 91-year-old man with NMIBC with high-risk features that had failed multiple intravesical therapies...
September 2017: Urology Case Reports
https://www.readbyqxmd.com/read/28601885/safety-and-efficacy-of-intravesical-bacillus-calmette-gu%C3%A3-rin-immunotherapy-in-patients-with-non-muscle-invasive-bladder-cancer-presenting-with-asymptomatic-bacteriuria-a-systematic-review
#5
Sławomir Poletajew, Piotr Zapała, Piotr Radziszewski
Intravesical Bacillus Calmette-Guérin (BCG) immunotherapy in bladder cancer patients with asymptomatic bacteriuria (ABU) remains a matter of debate. The aim of this systematic review was to present available evidence on the safety and efficacy of BCG immunotherapy in patients with ABU. A literature search within the Medline and the Embase databases was conducted with the following search terms: adverse events, bacteriuria, BCG, bladder cancer, cystitis, infection, pyuria, side effects and urinary tract infection (UTI)...
June 10, 2017: Urologia Internationalis
https://www.readbyqxmd.com/read/28600516/systematic-review-and-cumulative-analysis-of-the-combination-of-mitomycin-c-plus-bacillus-calmette-gu%C3%A3-rin-bcg-for-non-muscle-invasive-bladder-cancer
#6
Tuo Deng, Bing Liu, Xiaolu Duan, Tao Zhang, Chao Cai, Guohua Zeng
This systematic review and cumulative analysis aimed to explore the efficacy and safety of the combination of intravesical mitomycin C (MMC) plus bacillus Calmette-Guerin (BCG) for non-muscle-invasive bladder cancer (NMIBC) patients. A comprehensive literature search using Pubmed, Embase, Medline, Cochrane Library, CBM, CNKI and VIP databases was performed to identify studies applying intravesical MMC plus BCG therapy on NMIBC patients up to June 2016. Summarized unadjusted odds ratios (ORs) with 95% confidence intervals (CIs) were calculated to assess the efficacy and safety of the combination therapy...
June 9, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28588015/intravesical-bcg-induces-cd4-t-cell-expansion-in-an-immune-competent-model-of-bladder-cancer
#7
Max Kates, Thomas Nirschl, Nikolai A Sopko, Hotaka Matsui, Christina M Kochel, Leonardo O Reis, George J Netto, Mohammad Hoque, Noah M Hahn, David J McConkey, Alex S Baras, Charles G Drake, Trinity J Bivalacqua
Intravesical BCG immunotherapy is the standard of care in treating non-muscle invasive bladder cancer, yet its mechanism of action remains elusive.  Both innate and adaptive immune responses have been implicated in BCG activity. Although prior research has indirectly demonstrated the importance of T cells and shown a rise in CD4(+) T cells in bladder tissue after BCG, T-cell subpopulations have not been fully characterized.  We investigated the relationship between effector and regulatory T cells in an immune competent, clinically relevant rodent model of bladder cancer...
June 6, 2017: Cancer Immunology Research
https://www.readbyqxmd.com/read/28583311/next-generation-sequencing-of-nonmuscle-invasive-bladder-cancer-reveals-potential-biomarkers-and-rational-therapeutic-targets
#8
Eugene J Pietzak, Aditya Bagrodia, Eugene K Cha, Esther N Drill, Gopa Iyer, Sumit Isharwal, Irina Ostrovnaya, Priscilla Baez, Qiang Li, Michael F Berger, Ahmet Zehir, Nikolaus Schultz, Jonathan E Rosenberg, Dean F Bajorin, Guido Dalbagni, Hikmat Al-Ahmadie, David B Solit, Bernard H Bochner
BACKGROUND: Molecular characterization of nonmuscle invasive bladder cancer (NMIBC) may provide a biologic rationale for treatment response and novel therapeutic strategies. OBJECTIVE: To identify genetic alterations with potential clinical implications in NMIBC. DESIGN, SETTING, AND PARTICIPANTS: Pretreatment index tumors and matched germline DNA from 105 patients with NMIBC on a prospective Institutional Review Board-approved protocol underwent targeted exon sequencing analysis in a Clinical Laboratory Improvement Amendments-certified clinical laboratory...
June 2, 2017: European Urology
https://www.readbyqxmd.com/read/28577928/renal-tuberculosis-following-intravesical-bcg-for-high-grade-non-muscle-invasive-bladder-cancer
#9
Neha Sihra, Nonaka Diasuke, Ramesh Thurairaja, Muhammad Shamim Khan, Sachin Malde
A 47-year-old man presented to the urology department with visible haematuria. He was found to have a high-grade non-muscle-invasive transitional cell carcinoma of the bladder and was subsequently treated with intravesical BCG instillations. On routine surveillance CT scan following treatment he was found to have multiple rounded areas of low density in the right kidney, suspicious for renal malignancy. He underwent renal biopsy which revealed necrotising granulomatous inflammation suggestive of mycobacterial infection...
May 31, 2017: Urology
https://www.readbyqxmd.com/read/28575173/health-care-associated-mycobacterium-bovis-bcg-infection-in-cancer-patients-without-prior-bcg-instillation
#10
Y Meije, J Martínez-Montauti, J A Caylà, J Loureiro, L Ortega, M Clemente, X Sanz, M Ricart, M J Santomà, P Coll, M Sierra, M Calsina, M Vaqué, I Ruiz-Camps, C López-Sánchez, M Montes, A Ayestarán, J Carratalà, A Orcau
Background: Bacille Calmette-Guérin (BCG), an attenuated strain of Mycobacterium bovis, is widely used as adjunctive therapy for superficial bladder cancer. Intravesical administration of BCG has been associated with systemic infection. Disseminated infection due to M. bovis is otherwise uncommon. Methods: After identification of three patients with health-care associated BCG infection (HCBCGI) who had never received intravesical BCG administration, an epidemiologic study was performed...
May 29, 2017: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
https://www.readbyqxmd.com/read/28567336/management-of-hepatic-granulomatous-tuberculosis-after-bcg-therapy-for-bladder-cancer
#11
Mohsen Ayati, Mohammad Reza Nowroozi, Afshin Mortazavi, Solmaz Ohadian Moghadam, Hossein Ghorani
BCG therapy is used as a treatment in bladder cancer. Intravesical administration of Bacillus Calmette-Guérin is used as a treatment method in superficial bladder cancer. While it is commonly effective, some serious side effects may occur. We hereby report a 65-year-old man who developed granulomatous hepatitis as a complication following BCG therapy. He was treated successfully with antitubercular therapy and prednisolone.
July 2017: Urology Case Reports
https://www.readbyqxmd.com/read/28567334/case-presentation-lung-consolidation-as-sequelae-of-bcg-sepsis-after-combined-intravesical-and-intraurethral-bcg
#12
Jeffrey Strich, Sam Brancato, Rebecca Dolan, Mahir Maruf, Mohammad R Siddiqui, Thomas Sanford, Christa Zerbe, Piyush K Agarwal
BCG sepsis is rarely seen with modern intravesical therapy and therefore its presentation may not be apparent to recently trained urologists. We describe BCG sepsis occurring in a patient treated with combined intravesical and intraurethral BCG which resulted in lung consolidation with acid-fast bacilli requiring cessation of BCG and initiation of systemic antibiotic therapy.
July 2017: Urology Case Reports
https://www.readbyqxmd.com/read/28516156/single-arm-phase-i-ii-study-of-everolimus-and-intravesical-gemcitabine-in-patients-with-primary-or-secondary-carcinoma-in-situ-of-the-bladder-who-failed-bacillus-calmette-guerin-nct01259063
#13
Guido Dalbagni, Nicole Benfante, Daniel D Sjoberg, Bernard H Bochner, S Machele Donat, Harry W Herr, Asia S Mc Coy, Alicia J Fahrner, Caitlyn Retinger, Jonathan E Rosenberg, Dean F Bajorin
Background: Standard treatment for BCG-refractory urothelial cancer is radical cystectomy. Identification of active agents is clearly warranted. Objective: To determine a safe dose of oral everolimus in combination with standard intravesical gemcitabine and to evaluate the efficacy of this combination. Methods: Patients with carcinoma in situ refractory to intravesical bacillus Calmette-Guérin and refusing cystectomy were eligible. Patients in the phase I part of the trial received one of three dose levels of oral everolimus...
April 27, 2017: Bladder Cancer
https://www.readbyqxmd.com/read/28493171/immunotherapy-in-urothelial-cancer-recent-results-and-future-perspectives
#14
REVIEW
Matthew S Farina, Kevin T Lundgren, Joaquim Bellmunt
Cytotoxic chemotherapy has been the only systemic treatment of locally advanced and metastatic urothelial carcinoma for decades. Long-term survival remains stagnant around 12-14 months for patients with advanced disease who have progressed on or recurred after receiving first-line platinum-based chemotherapy. Improving clinical outcomes for patients with urothelial carcinoma in all disease settings requires the development of novel treatments, especially for patients who failed on first-line chemotherapy. Since the discovery of intravesical Bacillus-Calmette Guerin (BCG) in the 1970s for non-muscle invasive disease, there have not been any major breakthrough drugs that exploit the immune-sensitivity of bladder cancer until recently...
May 11, 2017: Drugs
https://www.readbyqxmd.com/read/28471272/determining-optimal-maintenance-schedules-for-adjuvant-intravesical-bacillus-calmette-guerin-immunotherapy-in-non-muscle-invasive-bladder-cancer-a-systematic-review-and-network-meta-analysis
#15
Zixiong Huang, Huixin Liu, Yizeng Wang, Chunfang Zhang, Tao Xu
OBJECTIVES: To figure out optimal bacillus Calmette-Guerin (BCG) maintenance schedules for non-muscle-invasive bladder cancer (NMIBC) patients by comparing different schedules in a systematic review using conventional and network meta-analysis. MATERIALS AND METHODS: Literature was searched in the databases of Medline, Embase, Cochrane library, Clinicaltrials.gov, Wanfang, CNKI and SinoMed in April 2016 and 9 randomized clinical trials comparing intravesical BCG maintenance therapy with BCG induction-only therapy or comparing different BCG maintenance schedules (induction-only, 1 year, 1...
June 6, 2017: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/28469275/prognostic-value-of-impaired-estimated-glomerular-filtration-rate-in-intravesical-bcg-treated-non-muscle-invasive-bladder-cancer-patients
#16
Bum Sik Tae, Jung Kwon Kim, Minyong Kang, Chang Wook Jeong, Cheol Kwak, Hyeon Hoe Kim, Ja Hyeon Ku
To evaluate the influence of patient-associated parameters and comorbities, with a special focus on renal function after intravesical adjuvant bacillus Calmette-Gue´rin (BCG) immunotherapy in patients with non-muscle-invasive bladder cancer (NMIBC). We retrospectively reviewed the medical records of patients treated from October, 1991 to December, 2013 at Seoul National University who were diagnosed with NMIBC and treated with intravesical BCG. A total of 344 patients who were diagnosed with NMIBC and treated with intravesical BCG were enrolled in this study...
May 3, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28457495/adjuvant-intravesical-treatment-for-nonmuscle-invasive-bladder-cancer-the-importance-of-the-strain-and-maintenance
#17
F Guerrero-Ramos, A Lara-Isla, J Justo-Quintas, J M Duarte-Ojeda, F de la Rosa-Kehrmann, F Villacampa-Aubá
BACKGROUND AND OBJECTIVE: Intravesical Bacille Calmette-Guérin (BCG) is essential for preventing the recurrence and progression of superficial bladder tumours. The aim of our study was to compare the efficacy and toxicity of the Connaught and Tice strains, as well as the importance of the maintenance regimen. MATERIAL AND METHODS: We retrospectively reviewed 110 patients with superficial bladder tumours who underwent adjuvant endovesical treatment. The patients were distributed into 3 groups, based on whether the treatment was with the Connaught strain, the Tice strain or both sequentially...
April 27, 2017: Actas Urologicas Españolas
https://www.readbyqxmd.com/read/28406993/topical-and-systemic-immunoreaction-triggered-by-intravesical-chemotherapy-in-an-n-butyl-n-4-hydroxybutyl-nitorosamine-induced-bladder-cancer-mouse-model
#18
Shunta Hori, Makito Miyake, Yoshihiro Tatsumi, Sayuri Onishi, Yosuke Morizawa, Yasushi Nakai, Nobumichi Tanaka, Kiyohide Fujimoto
Intravesical bacillus Calmette-Guerin (BCG) treatment is the most common therapy to prevent progression and recurrence of non-muscle invasive bladder cancer (NMIBC). Although the immunoreaction elicited by BCG treatment is well documented, those induced by intravesical treatment with chemotherapeutic agents are much less known. We investigated the immunological profiles caused by mitomycin C, gemcitabine, adriamycin and docetaxel in the N-butyl-N-(4-hydroxybutyl) nitrosamine (BBN)-induced orthotopic bladder cancer mouse model...
2017: PloS One
https://www.readbyqxmd.com/read/28406148/bladder-cancer
#19
REVIEW
Oner Sanli, Jakub Dobruch, Margaret A Knowles, Maximilian Burger, Mehrdad Alemozaffar, Matthew E Nielsen, Yair Lotan
Bladder cancer is a highly prevalent disease and is associated with substantial morbidity, mortality and cost. Environmental or occupational exposures to carcinogens, especially tobacco, are the main risk factors for bladder cancer. Most bladder cancers are diagnosed after patients present with macroscopic haematuria, and cases are confirmed after transurethral resection of bladder tumour (TURBT), which also serves as the first stage of treatment. Bladder cancer develops via two distinct pathways, giving rise to non-muscle-invasive papillary tumours and non-papillary (solid) muscle-invasive tumours...
April 13, 2017: Nature Reviews. Disease Primers
https://www.readbyqxmd.com/read/28402764/ensuring-access-to-injectable-generic-drugs-the-case-of-intravesical-bcg-for-bladder-cancer
#20
Benjamin J Davies, Thomas J Hwang, Aaron S Kesselheim
In November 2016, one of the two manufacturers of bacille Calmette–Guérin (BCG) informed health care providers that it planned to exit the market in mid-2017. Intravesical immunotherapy with BCG is the standard of treatment for preventing recurrence and disease progression in high-risk patients..
April 13, 2017: New England Journal of Medicine
keyword
keyword
7101
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"